Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Bl, Sergeyev"'
Publikováno v:
Europe PubMed Central
Serum anti-(GalNAcβ) and anti-para-Forssman disaccharide (PF(di), GalNAcβ1--3GalNAcβ) IgG levels were earlier found to be related to histological grading and progression of gastrointestinal cancer.To study the relation of serum antibodies level to
The characterization of IgG antibodies to GalNAc beta-terminated glycans of gastric cancer survivors
Publikováno v:
Europe PubMed Central
The elevated anti-GalNAcβ IgG level of serum was shown to be associated with the significantly better survival of patients with gastrointestinal cancer.To characterize the specificity of IgG antibodies to GalNAcβ-terminated glycans of long-term gas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::24419c13d0f426907d5c9e1c27f722ad
http://europepmc.org/abstract/med/24691283
http://europepmc.org/abstract/med/24691283
Publikováno v:
Europe PubMed Central
Earlier we found two unusual IgG-antibody specificities to GalNAc beta and GalNAc beta1-3GalNAc beta (para-Forssman disaccharide, PFdi) carbohydrate ligands in human serum. The aim of the study was to evaluate whether elevated antibody levels are rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3d538a5eb741d1aa70d5fda4fcfe020d
http://europepmc.org/abstract/med/17431391
http://europepmc.org/abstract/med/17431391
Autor:
Smorodin EP; Department of Oncology and Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia., Sergeyev BL; Department of Oncology and Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia.
Publikováno v:
Experimental oncology [Exp Oncol] 2016 Jun; Vol. 38 (2), pp. 117-21.
Autor:
Smorodin EP; Department of Oncology & Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia., Sergeyev BL; Department of Oncology & Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia., Kurtenkov OA; Department of Oncology & Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia.
Publikováno v:
Experimental oncology [Exp Oncol] 2014 Mar; Vol. 36 (1), pp. 38-43.
Autor:
Smorodin EP; Department of Oncology & Immunology, National Institute for Health Development, Hiiu 42, 11619 Tallinn, Estonia. jevgeni.smorodin@tai.ee, Kurtenkov OA, Sergeyev BL
Publikováno v:
Experimental oncology [Exp Oncol] 2013 Jun; Vol. 35 (2), pp. 89-92.
Autor:
Smorodin EP; Department of Oncology and Immunology, National Institute for Health Development, Tallinn, Estonia. jevgeni.smorodin@tai.ee, Kurtenkov OA, Sergeyev BL, Branovets JS, Izotova JG, Formanovsky AA
Publikováno v:
Journal of immunoassay & immunochemistry [J Immunoassay Immunochem] 2011; Vol. 32 (3), pp. 170-90.
Autor:
Smorodin EP; Department of Oncology and Immunology, National Institute for Health Development, Hiiu 42, Tallinn 11619, Estonia. jevgeni.smorodin@tai.ee, Kurtenkov OA, Sergeyev BL, Kodar KE, Chuzmarov VI, Afanasyev VP
Publikováno v:
World journal of gastroenterology [World J Gastroenterol] 2008 Jul 21; Vol. 14 (27), pp. 4352-8.
Autor:
Smorodin EP; Department of Oncology & Immunology, National Institute for Health Development, Tallinn, Estonia. evgeni.smorodin@tai.ee, Kurtenkov OA, Sergeyev BL, Chuzmarov VI, Afanasyev VP
Publikováno v:
Experimental oncology [Exp Oncol] 2007 Mar; Vol. 29 (1), pp. 61-6.
Autor:
Smorodin EP; Institute of Experimental & Clinical Medicine, Hiiu 42, 11619 Tallinn, Estonia. smorodin@ekmi.ee, Kurtenkov OA, Sergeyev BL, Pazynina GV, Bovin NV
Publikováno v:
Glycoconjugate journal [Glycoconj J] 2004; Vol. 20 (2), pp. 83-9.